Sentiment Lifts On Vaccine Optimism and EU Stimulus Deal
Fiona Cincotta July 21, 2020 4:20 PM
Vaccine optimism and EU fiscal stimulus is boosting the mood in the market on Tuesday.
A combination of vaccine optimism and fiscal stimulus is boosting the mood in the market on Tuesday. Encouraging results from Oxford’s vaccine candidate, in addition to EU leaders agreeing to a €750 billion Recovery Fund is overshadowing rising tension between the UK and China and soaring covid numbers in California.
Vaccine optimism continues to underpin the market after Oxford /AstraZeneca reported a good immune response in Phase 3 trials for its vaccine candidate, which crucially had no adverse side effects. Given that a vaccine is the surest, quickest and possibly the only way to return to pre-coronavirus economic growth and normalcy, investors are particularly sensitive to vaccine headlines.
Brexit talks & Mike Pompeo visits
Brexit talks are due to restart today. Hopes and expectations of any agreement are low after recent talks’ disappointment. US Secretary of State Mike Pompeo is also in the UK to discuss China, 5G and free trade deal with Prime Minister Boris Johnson. His arrival comes after Britain suspended its extradition treaty with Hong Kong in retaliation to the national security law imposed by China. The move has stoked tensions between the UK and China accelerating deteriorating relations
There is no high impacting economic data due to be released leaving sentiment to drive the markets. Coronavirus statistics are also likely to remain in focus, particularly after California reported almost 12,000 new cases, taking the total to 400,000. If it were a country it would be up there with some of the highest infected countries.
From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.